Growing Global Aging Population And Its Impact On The Gastric Cancer Drug Market Is Supporting Development Across The Gastric Cancer Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Gastric Cancer Drugs Market From 2026 To 2030?

The gastric cancer drugs market size has witnessed robust expansion in recent years. It is forecast to increase from $4.9 billion in 2025 to $5.39 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. This historical growth can be attributed to several factors including the rising incidence of gastric cancer, a lack of awareness regarding early detection, the continued reliance on conventional chemotherapy, the increasing preference for hospital-based treatment, and the elevated prices of branded medications.

The gastric cancer drugs market size is set to expand rapidly over the next few years, with projections indicating it will reach $8.14 billion by 2030, exhibiting a compound annual growth rate of 10.9%. This expansion throughout the forecast period is primarily driven by progress in targeted therapies, the growing acceptance of immunotherapy, the wider adoption of precision medicine, the introduction of new oral and injectable drug formulations, and increased financial backing for cancer research from both government and private sectors. Significant trends anticipated during this period include customized gastric cancer treatments, the evolution of targeted drug delivery methods, a greater emphasis on combination therapies, the expansion of outpatient cancer treatment services, and improvements in supportive care and symptom management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Important Drivers Are Powering The Gastric Cancer Drugs Market Growth?

The future expansion of the gastric cancer drug market is projected to be fueled by the rising worldwide elderly population. This demographic trend describes a scenario where a substantial portion of inhabitants in a country or area are older, usually 65 years old or more. This phenomenon emerges from prolonged increases in life expectancy coupled with declining birth rates, leading to a greater share of older individuals within the total populace. Elderly patients might exhibit reduced tolerance for some cancer therapies, like surgical procedures or chemotherapy. Consequently, a demand arises for more customized treatment approaches, including pharmaceutical interventions, to cater to the unique requirements and sensitivities of older patients. For example, in July 2024, the UK Parliament’s House of Commons Library, a UK-based government administration, reported that in 2022, 12.7 million individuals aged 65 or older resided in the UK, constituting 19% of the total population. This figure is anticipated to increase to 22.1 million by 2072, making up 27% of the population. Therefore, the gastric cancer drug market is expected to expand in the future, propelled by the increasing demographic of older individuals.

How Are Different Segment Groups Identified Within The Gastric Cancer Drugs Market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Which Trends Are Shaping The Gastric Cancer Drugs Market Landscape?

Companies operating within the gastric cancer drugs market are concentrating on developing innovative products, including CLDN18.2-targeted treatments, to enhance therapy efficacy and provide more personalized options for patients. A CLDN18.2-targeted treatment denotes therapies specifically designed to target claudin 18.2 (CLDN18.2), a protein predominantly expressed in certain epithelial tissues, such as the gastric epithelium. For instance, in October 2024, Astellas Pharma Inc., a Japan-based company, secured approval from the Food and Drug Administration (FDA), a US-based federal agency dedicated to protecting public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) is the first and only CLDN18.2-targeted treatment utilized for advanced gastric and gastroesophageal junction cancer in patients whose tumors are CLDN18.2 positive. The treatment is administered in conjunction with fluoropyrimidine- and platinum-based chemotherapy regimens. It is indicated for adults diagnosed with locally advanced unresectable negative gastric or gastroesophageal junction cancer adenocarcinoma.

Which Firms Are Competing In The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS

Access The Complete Gastric Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Region Holds The Largest Share In The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastric Cancer Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795